Telmisartan effectiveness on left ventricular MAss reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension - a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months - rationale and study design

Tools

Item Type:	Article
Title:	Telmisartan effectiveness on left ventricular MAss reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension - a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months - rationale and study design
Creators Name:	Friedrich, M.G., Dahlof, B., Sechtem, U., Unger, T., Knecht, M. and Dietz, R.
Abstract:	The Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) trial will assess the effect of the angiotensin II (Ang II) receptor blocker, telmisartan, on left ventricular hypertrophy (LVH) compared with the β-blocker, metoprolol, at similar antihypertensive doses. The rationale is that antihypertensives reduce LVH, a cardiac adaptation to pressure overload, principally by pressure-related effects. Ang II plays a key role in pressure-independent mechanisms causing LVH, and angiotensin-converting enzyme (ACE) inhibitors induce more pronounced LVH regression than some other antihypertensives. Blocking Ang II Type 1 receptors may be more effective than ACE inhibition in reducing LVH. TELMAR is a prospective, randomised, double-blind, double-dummy, parallel-group trial. A total of 140 patients (age 18—80 years) with uncontrolled essential hypertension (mean daytime systolic blood pressure [SBP] ≥140 mmHg or diastolic blood pressure [DBP] ≥90 mmHg and night-time SBP ≥120 mmHg or DBP ≥70 mmHg, measured by ambulatory blood pressure monitoring [ABPM]) and left ventricular mass index related to height (LVMI) >0.8 g/cm for females, >1.1 g/cm for males (defined by magnetic resonance imaging [MRI]) will be randomised to once-daily telmisartan or metoprolol. The telmisartan dose will be 40 mg for the first two weeks, 80 mg for 5.5 months and 40 mg for the last two weeks. Metoprolol will be given at a dose of 47.5 mg for two weeks, 95 mg for 5.5 months and 47.5 mg for two weeks. Concomitant add-on medication with hydrochlorothiazide and amlodipine will be allowed. The primary endpoint is the percentage change in LVMI at treatment end versus baseline, using MRI. Secondary variables include blood pressure changes and response rates assessed by ABPM and manual cuff sphygmomanometry, and end-systolic wall stress, systolic left ventricular function (LVF) and diastolic LVF determined by MRI. A separate study was performed prior to the main trial to define the normal range of MRI data in an age-matched population.
Keywords:	Left ventricular hypertrophy, Angiotensin II receptor blocker, Telmisartan, β-blocker, Metoprolol
Source:	Journal of the Renin Angiotensin Aldosterone System
ISSN:	1470-3203
Volume:	4
Page Range:	234-243
Date:	1 January 2003
Official Publication:	https://doi.org/10.3317/jraas.2003.038
PubMed:	View item in PubMed

Repository Staff Only: item control page